

## Britannia Pharmaceuticals Limited

[View the current Britannia Pharmaceuticals Limited Page on BioPortfolio.com](http://www.bioportfolio.com/bioporporate/20170-Britannia+Pharmaceuticals+Limited.html)

(<http://www.bioportfolio.com/bioporporate/20170-Britannia+Pharmaceuticals+Limited.html>)

### Contact Details:

**41-51 Brighton Road  
Redhill  
Surrey  
RH1 6YS  
United Kingdom**

Tel: (+44) 01737 773741

Fax: (+44) 01737 762672

Email:

Britannia Pharmaceuticals Limited, located in the South of England, is a niche pharmaceutical company specialising in products for diseases with orphan indications (small patient populations) which are normally not developed by larger pharmaceutical companies. It is our primary focus search for and develop pharmaceutical products for special patient groups, expanding our know-how in the disease areas our products serve, and to make these products available internationally.

The company has built its success and ability to develop active compounds into fully licensed pharmaceutical preparations, with particular expertise in clinical trials, formulation work, registration, marketing and sales. Our primary expertise is in the development of products for the areas of Parkinson's disease and opiate detoxification. We have been active with UK neurologists and geriatricians since 1981, starting with the marketing and development of the product Eldepryl (selegiline hydrochloride). These relationships helped us to identify the benefit of and need for apomorphine as a rescue treatment for Parkinson's disease sufferers, leading to the development of our APO-go products

### Recent Publications by Britannia Pharmaceuticals Limited:



- [Lofexidine in opiate withdrawal: a safety and usage survey.](#)

*A retrospective, observational survey, conducted under the remit of the...* 26th November, 2008  
Britannia Pharmaceuticals Limited, Redhill, Surrey, UK.- *Pharmacoepidemiol Drug Saf.* 2000  
Jan;9(1):43-7. ([DOI Direct Link](#))

**Press Releases on Britannia Pharmaceuticals Limited:**

<p><a href="#">Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients</a></p>	<p>23rd November, 2009</p>	<p>Cumberland Pharmaceuticals Inc.</p>	<p>NASHVILLE, Tenn., Nov. 23 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced positive new top-line results from a study evaluating the safety and efficacy of</p>
<p><a href="#">Visage Imaging(R) Wins \$1.4 Million Lake Imaging Deal With Visage(R) 7 Enterprise Solution</a></p>	<p>23rd November, 2009</p>	<p>Visage Imaging Inc.</p>	<p>ANDOVER, Mass., Nov. 23 /PRNewswire-FirstCall/ -- Visage Imaging® Inc., a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME) announced today a signed deal to provide Lake Imaging, one of</p>
<p><a href="#">Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009</a></p>	<p>23rd November, 2009</p>	<p>Lexicon Pharmaceuticals, Inc.</p>	<p>THE WOODLANDS, Texas, Nov. 23 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXXRX), announced today that top-line data from its Phase 2 clinical study with</p>
<p><a href="#">Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders</a></p>	<p>23rd November, 2009</p>	<p>Isis Pharmaceuticals, Inc.</p>	<p>CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Dear Isis Supporters and Shareholders, I would like to start by thanking you for your continuing support of Isis. We believe we are at one of the</p>
<p><a href="#">Oceanside Pharmaceuticals Announces Launch of Librax(R) AG</a></p>	<p>23rd November, 2009</p>	<p>Valeant Pharmaceuticals International</p>	<p>ALISO VIEJO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Oceanside Pharmaceuticals, part of Valeant Pharmaceuticals International (NYSE: VRX), today announced that it has now launched chlordiazepoxide</p>

**Britannia Pharmaceuticals Limited Clinical Trials:**



- [Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.](#)





## Britannia Pharmaceuticals Limited Patents:

- 7473416- [Medicaments for asthma treatment](#)
- 7273604- [Anti-asthmatic combinations comprising surface active phospholipids](#)
- 6824761- [Anti-asthmatic combinations comprising surface active phospholipids](#)
- 6719960- [Use of phospholipids for the manufacture of a medicament for the prevention of adhesions](#)
- 6482391- [Medicaments for asthma treatment](#)
- 6395295- [Use of surface active agent for the manufacture of a medicament for treatment of disorders of the middle ear](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

